initi hold pt hiv
deep-div patent cliff prep
stabl hiv enough need see growth come
gilead compani construct new manag
helm believ hiv busi offer stabl revenu
time think difficult see upsid name see
grow busi market oppi filgotinib
larg expect uptak could slow see show stori
bear case assum littl prep post gener truvada zero
credit pipelin termin valu would reflect complet
lack faith compani alloc capit appropri grow
think share trade level gilead
past trade zero termin valu lack pipelin visibl
deep dive gilead hiv cliff investor often worri
conclud unlik biktarvi prefer regimen guidelin
substitut point gener drug kol check also
support model peak us/row share assum
share npv page
ask dynam hiv app type assumpt
hiv see dcf impact
descovi prep could provid upsid doc check optimist
descovi truvada taf market truvada go gener mid
doc spoke said would unlik use descovi
gener truvada gilead convert current market descvoy
would upsid prep deep dive
stock pullback view ceo laid clear
vision intend turn around compani littl visibl
pipelin filgotinib cellular therapi confid take time
phase readout galapago glpg nr like wont enough
investor today
valuat risk
pt deriv use probabl adjust dcf use
discount rate appropri larg cap stage biotech pipelin
uncertainti assign share descovi prep probabl
peak sale filgotinib risk includ poorer biktarvi uptak
price reimburs gener pipelin clinic trial risk failur alloc
tr target
gilead hold wait growth visibl
page
page
pm summari initi hold pt
page
pm summari initi hold pt
gilead thesi simpl see stabil hiv busi think investor need insight
growth
believ core busi hiv like continu beat expect
level see upsid month time-frame greater confid biktarvi domin
new manag abil believ implement pipelin chang
cours month make clear direct compani head growth
return howev need chang first gain confid
help investor understand confid hiv stabil gilead deep-div hiv
patent cliff prep creat hiv app investor appli assumpt
patient convert biktarvi latest pill hiv patient longest
patent life extend hiv revenu protect deep dive
discuss potenti cliff hiv revenu wont fall cliff current
stock trade compani disappear along biktarvi minim credit
 product prep capit alloc
stock pullback understand view given ceo laid clear vision
intend turn around compani littl visibl pipelin
alway case gilead filgotinib jak inhibitor cellular therapi
confid take time phase readout galapago glpg nr like wont
enough investor today
page
catalyst nash management chang stock-mov catalyst weak
strh research compani reportsfacset
strh research compani report factset
page
ask hiv app dynam model input assumpt
gilead good life cycl extens done hiv think still
underappreci street
second street give minim credit life cycl extens prep addit
descovi compani also inject think investor fulli understand
opportun prep credit upsid
creat new app show impact biktarvi ep top-line grow greater
expect impact prep descovi goe gener futur prep drug dont uptak
page
switch app market sharepeak market share share ususex-usatripla dcf valu switch new total gilead total hiv revenu truvada hiv truvada prep descovi hiv descovi prep oral potenti launch str truvada/taf sale inc
hiv busi stabl investor look addit product add top-line
hiv sale continu make total sale
page
model hiv portfolio give credit pipelin littl credit descovi prep
growth slow
page
consensu
page
data catalyst near-term look commerci execut
look ahead filgotinib potenti approv remain conserv commerci
execut gild first foray inflamm market compet
establish big pharma player strong contracting/reb
conserv peak penetr ra market peak sale
page
view floor
take termin valu biktari patent expir assum product
pipelin execut fair valu stock goe use zero termin valu
seem unrealist gilead trade zero termin valu post patent cliff
compani littl insight growth pipelin
differ filgotinib glpg product arent fulli reflect model
page
scenariobear impact dcf dcf dcf credit filgotinibno credit filgotinib credit descovi rate peak sale descovi prep peak penetr credit descovi prepassumptionstermin yearfv gilead scienc inc
compani construct new manag on-going restructur
sever senior manag chang oday take helm march
await see clarif execut strateg vision expect get updat
learn key prioriti present recent earn call
pipelin focu leverag glpg collabor highli product engin
sever pipelin product complementari gild strength focu exist pipelin
hiv filgotinib potenti approval/launch
optim commerci deliveri focu remain execut current new launch
personnel bring right team togeth right time
presid chief technic offic
presid ceo effect aug
evp oncolog therapeut kite
cso/head
cfo
pact pharma evp technic oper kite sinc march
svp earli clinic develpo genentech research earli
us head presid nv corp na head nv oncolog
presid head larg market divis bm
current serv evp corpor develop strategi
page
investor get confid growth key question view
hiv busi key remain confid maintain leadership hiv given follow
prep grow truvada soon descovi major prep commercially-insur peopl mean
better medicare/medicaid see boost price alon prep patient
dont think peopl model model descovi prep share
convers descovi eventu inject could occur model
continu robust launch biktarvi recommend hiv panel track sinc
launch feb biktarvi gain share upsid model
gilead feel confid abil execut inflamm investor skeptic ra drug
typic slow launch take time entrench market place longer time
horizon invest base filgotinib
filgotinib second enter market ra howev one risk without manta studi
could get warn label filgotinib second ra ibd categori
move prioriti potenti launch filgotinib could crohn
street model
nr expect gener sale ra alon think jak class could
larg assum indic investor skeptic gilead assum wac price
low ra share sale could conserv everi addit
credit filgotinib could see addit dcf
could catalyst glpg deal gain asset earli investor get excit
page
notabl pushback usual guid street well typic beat guidanc
upper end revenu guidanc
lower end revenu guidanc
page
model pt use dcf discount rate termin valu
appli higher discount rate instead account lack visibl growth
page
ebit base work present valu growth termin inc
upsid risks/pushback thesi like investor
pushback gilead cheap trade trade level impli zero credit prep beyond
truvada capit alloc includ pipelin could attract long-term
valu investor could see enter name uncertain market
pushback also like manag vision compani becom clearer
year begin could stock would go
strh rebutt gilead new manag team may take time vision
implement ceo say expect evolut vs revolut one risk stock
doesnt move look like compani grow becom diversifi
pushback gilead expertis descovi show better safeti almost better efficaci
trial inject believ complianc deal prep popul health risk
believ past gilead switch patient got new patient onto better drug also
believ number
strh rebuttl descovi take share truvada gener shortli doc check
excit desovi assign long act also take time
pushback filgotinib new oa ipf asset provid growth
strh rebutt fair think confid asset take time think investor
want near term confid late stage asset grow jak market believ lot
skeptic show stori ipf trial futil analysi oa phase
page
management comp line biotech investor expect
manag compens align well sharehold interest
overal compens plan appear line sharehold interest name execut offic elig
earn incent bonu base individu perform goal well corpor goal relat product
develop advanc clinic studi compens execut structur around
achiev corpor goal mileston year base subject object perform
goal determin board director
page
deep dive hiv patent cliff
page
hiv get confid hiv busi stabil upsid potenti
truvada goe gener sept follow teva teva hold gilbert settlement
realiz clip expect launch long-act oral drug ahead
patent cliff fro descovi complera odefsey
strh research compani report
launch
page
hiv get confid hiv busi stabil upsid potenti
start hiv key investor question get help get confid gilead hiv
revenu stabl wont erod variou time point cheaper drug come market
address cliff individu cliff impact
page
thing know hiv guidelin driven
goal hiv arv reduc hiv viral load undetect level preserv t-cell
delay/prev viral resist hiv-rel morbid mortal
initi hiv treatment typic single-tablet regimen avoid pill burden improv
incid hiv rate stabl per year us
major hiv patient drug sever decad older
doc check note switch patient multi-tablet regimen
singl tablet regimen provid conveni increas complianc
page
nih panel rec concern reduc viral load resist safeti profil
integras inhibitor singl tablet regimen taf-bas regimen prefer
taf-bas regimen less impact renal biomark lower rate proteinuria tdf
associ smaller declin bmd tdf
page
drug check box
consider effect arv prefer regimen includ
lower pill burden single-tablet regimen prefer especi age hiv popul
drug fewer drug drug-drug interact requir food need taken
empti stomach gi effect neuropsychiatr effect
easier manag dose schedul
panel recommend initi art peopl hiv regimen
str singl tablet regimen daili hiv co-formul singl tablet combo therapi aim
reduc amount hiv bodi risk hiv transmiss prevent hiv advanc aid
protect immun system
page
drug guidelin regimen
page
drug manufacturercommentsdos recommendationbiktarvi bic/taf/ftc gildcontain taf unboost bictegravir ae profil includ diarrhea nausea tablet underli risk coronari heart tablet dailydescovi tivicay taf/ftc dtg gildcontain taf tablet dailydescovi isentress hd taf/ftc ral hd gildcontain taf unboost recommend tablet dailytruvada tivicay tdf/ftc dtg gildconsid bone tablet dailytruvada isentress hd tdf/ftc ral hd gildconsid bone densiti mg/al antacid tablet dailygenvoya evg/c/taf/ftc gildtaf fewer bone/kidney tox tdf tdf associ lower lipid level contain taf boost cobicistat drug-drug tablet daili w/foodstribild evg/c/tdf/ftc gildevg lower barrier resist dtg bic evg also associ ae nausea headach depression/suicid tablet daili w/foodpref initi art str integras inihibitor nucsinsti nrtispref initi art multi-t regimen daili dosingaltern initi art multi-tablet regimen daili dosinglegend abc abacavir arv antiretrovir bic bictegravir cobicistat dor doravirin drv darunavir dtg dolutegravir efv efavirenz evg elvitegravir ftc emtricitabin inst integras strand transfer inhibitor nnrt non-nucleosid revers transcriptas inhibitor nrti nucleosid revers transcriptas inhibitor pi proteas inhibitor rpv rilpivirin ral raltegravir str single-tablet regimen taf tenofovir alafenamid tdf tenofovir disoproxil fumarater recommend strong moder optionalr evid data random control tiral ii data form well-design non-random trial observ cohort studi long-term clinic outcom rel bioavailability/bioequival studi regimen comparison random switch studi expert opinionsourc strh research nihaltern initi art str gilead scienc inc
drug high prefer
page
drug manufacturercommentsdos tablet dailysymtuza drv/c/taf/ftc gildcontain taf boost cobicistat drug-drug tablet daili w/foodatripla efv/tdf/ftc gildatripla fallen favor b/c side effect profil efavirenz uniqu se profil includ neuropsychiatr effect groggi need taken night empti daili empti se profil daili empti stomachsymfi se profil daili empti stomachcomplera rpv/tdf/ftc gildconsid bone miner daili bone miner daili odefsey rpv/taf/ftc gildcaut patient depress histori suicid contraind ppi must taken food contain taf daili mealjuluca dtg/rpv viivcontain tivicay dtg whicih ae includ insomnia headach depression/suicid ideat weight gain daili empti stomachintegras inhibitor non-nuc insti one nnrti non-nuc nuc nnrti nrtisproteas inhibitor non-nucpi nrtisintegras inhibitor non-nucinsti one nrti gilead scienc inc
takeaway doc check treat hiv patient
theme convers doc cost access therapi conveni mani
pill mani per day side effect profil gild biktarvi note one top drug
prescrib treatment-nav patient switch older drug regimen
start new arv therapi doc prefer biktarvi triumeq first less frequent
dovato juluca newer drug less extens data
hiv patient life-long treatment doc consid se profil drug
prescribing/switch even gener come
patient older medic doc patient confid regimen
need switch newer drug
major patient doc treat switch atripla would use gener
atripla even cost lower prescrib move past atripla gener atripla-lik
compound due se profil
atripla fell favor efavarin uniqu se profil includ neuropsychiatr effect
groggi need taken empti stomach
multi-tablet regimen favor gener cimduo lamivudine/tdf similar compon
truvada market uptak weak despit incent stay
drug take regimen break two tablet challeng harder
manag mistak happen pharmaci run stock one tablet
page
takeaway doc check treat hiv patient
conveni se profil consider prescrib hiv treatment patient
atripla ae profil also put mani prescrib start therapi atripla
associ neuropsychiatr effect groggi must taken empti stomach night
doc say atripla first str mani patient first older patient may
stay use gener well thu switch atripla could
riski consid se profil drug
doc use boost drug genvoya less frequent integras inhibitor
boost covocistat make effect howev covocistat se caus drug-drug
interact also boost drug fraught resist problem
biktarvi doesnt requir booster signific data face resist
doc name biktarvi one top drug switch patient older drug str
simplic improv toler profil
even gener truvada tivicay come likelihood switch patient
expens drug gener one unlik doc prefer patient stabl current
regimen stay thu patient switch single-tablet biktarvi gener
truvada/tivicay multi-tablet combo unlik
page
takeaway doc check treat hiv patient
doc patient want option simpler treatment
certain patient want tri inject see get inject doctor offic
monthli everi month conveni take pill everi day
big thing hiv treatment inject less frequent dose daili oral pill
maintain treatment shift patient manufactur
viiv gsk nr nr develop every-two month inject
phase inject cabotegravir and/edur rilpivirin given everi two month could work
well monthli therapi
combo once-monthli inject fda review decis
develop once-weekli pill combin isentress raltegravir pifeltro doravirin
potenti implant durat month interest isentress high
potenc long half-lif lend formul oral implant drug
gilead also develop inject
page
overal maintain lead posit hiv market
maintain market share hiv drug viiv overal market
page
biktarvi also take share away hiv competitor market
page
dealt price pressur expens drug use
juluca bare sell even though cheaper
guidelin prefer biktarvi newer regimen
drug sold adap program state seen price increas accord
individu hiv medicin receiv federal/s program discount price
certain foreign countri gilead given patent exclus allow gener made
countri afford drug
page
drug manufacturerwac inhibitor inhibitor inhibitor nucsatripla inhibitor manufacturerwac tivicay taf/ftc dtg /viiv descovi tivicay isentress hd taf/ftc ral hd /mrck descovi isentress combo tivicay tdf/ftc dtg /viiv truvada tivicay isentress hd tdf/ftc ral hd /mrck truvada isentress combo initi art multi-t regimen daili altern initi art multi-tablet regimen daili inc
dealt price pressur
donat bottl truvada prep cdc transit
descovi given approv prep
individu us risk hiv current truvada
recent one payer tri incentiv patient use cheaper drug combo prefer
list result increas use pilot program halt
state program hiv drug gilead rais price
page
hiv busi base volum growth price increas
note price increas march
patient ndap price chang sinc
page
management see tailwind price pressur part
key takeaway management convers hiv tailwind given price pressur
tailwind prep usag thought sporad averag prep user scan take
month put formulari
base anecdot evid prescrib complianc lower prep approach chronic
user prep approach complianc similar chronic
tailwind vast major prep commerci insur major chronic volum
commerci mean averag price higher prep
vast major prep commerci channel advantag government payer take longer
includ someth formulari
chronic volum commerci payer medicar commerci mix greater
medicar within
also higher commerci plan
public/subsid channel adap lowest price increas product adap sinc
page
management see tailwind price pressur part
key takeaway management convers hiv tailwind given price pressur
hiv remain import part base busi account revenu focu
shift longer-act hiv regimen combat pill burden resist side effect
hiv guideline-driven market physician defer prefer single-t regiment
descovi approv earli octob prep mean month gener
truvada enter market sept manufactur
month convert mani truvada descovi prep
assum take truvada today chronic therapi str regimen go use
speak manag truvada revenu would go gener expos
look analogu prep one year convert taf genvoya launch
descovi alreadi commerci formulari prep ident dose chronic
truvada prep today switch descovi commerci insur cover truvada descovi
alreadi payer formulari
page
biktarvi reach full potenti yet
accord management biktarvi hasnt reach full potenti yet biktarvi
cannib hiv product also take market share competitor
step edit get biktarvi
new patient start biktarvi look label biktarvi check
high barrier resist
page
biktarvi continu grow w/w make total hiv trx weekli basi
biktarvi continu grow w/w sinc launch last februari
page
hiv rebutt key patent cliff
page
atripla goe gener likelihood go back atripla newer regimen unlik
doc check atripla fallen favor due ae profil includ neuropsychiatr
effect groggi need taken empti stomach
move back gener atripla seem unlik given guidelin recommend
base guidelin treatment-nav patient unlik start atripla experienc
patient like switch atripla given ae profil
howev truvada gx import prep alreadi given free truvada prep
management note prep typic young could move free drug
convert pay drug
page
isentress goe gener payer forc switch gener truvada combo
integras inhibitor base therapi prefer choic drug accord hiv guidelin
therefor investor concern merck isentress goe gener us
eu gener truvada plu isentress combin might use made
use payer instead gilead base regimen
rational like happen
isentress integras inhibitor avail two form singl tablet regimen
declin use sinc gilead integras inhibitor-bas come market
merck integras inhibitor isentress elev creatin phosophokinas elev muscl
given popul age averag hiv patient unlik combin
would prefer
doc also note regimen complic mistak happen sometim
pharmaci one pill
age hiv popul patient multi-drug pill may difficulti complianc
overal pill burden may comorbid
combo also like later new patient hiv patient gener truvada/tivicay
prefer tivicay viral load cut ideal
page
descovi goe gener patient forc use gener combo
descovi gilead taf base truvada combin pill proteas
inhibitor integras inhibitor merck isentress viiv tivicay integras inhibitor base
therapi prefer choic drug accord hiv guidelin
integras inhibitor prefer choic unlik patient str integras inhibitor
regimen forc switch non-integras inhibitor base regimen prefer
guidelin
gener isentress also avail ye gener compani could creat isentress/descovi
combo would cheaper gilead regimen
howev note tivicay integras inhibitor market liver
given popul age averag hiv patient unlik combin
would prefer
descovi claw back market share particip deeper penetr prep market
gener truvada enter market base superiority/safeti profil
strong prep awar invest brand unbrand campaign truvada
switch studi head-to-head truvada show numer higher efficaci
far statist superior safeti benefit real management doesnt think switch
studi truvada descovi need
page
viiv tivicay goe gener patient forc use gener combo
tivicay viiv integras inhibitor combin pill truvada descovi
effect goe gener us eu
howev tivicay risk neural tube birth defect concern combin
might ok women child bear age
integras liver warn disadvantag
addit point think patient biktarvi forc switch
doc check note incent prescrib prescrib combo tivicay descovi
dovato price combo less biktarvi medicare/medicaid
prefer prescrib choic
also note doc check also underscor patient well
start biktarvi may unlik switch back older gener
tivicay viral load cutoff label
dovato also note initi viral load cut per ml point studi
cut increas copies/ml like concern potenc
combin gilead dose viral load cut off biktarvi
dolutegravir label cite observ hepatotox monitor need
integras problem
page
viiv triumeq goe gener patient forc use gener combo
triumeq viiv integras inhibitor str abacavir backbon
abacavir howev associ cardiac complic prefer
hiv popul age averag hiv patient like time
drug go gener
would also expect patient drug mani patient switch
biktarvi
therefor think forc switch biktarvi patient ahead cliff unlik given
cardiac issu associ str safeti warn triumeq
doc check also note simplifi str regimen advantag complianc
triumeq includ integras liver warn bad backbon cv concern
page
gilead stribild/genovya go gener payer forc switch
gilead stribild/genvoya boost integras taf-bas str regimen
go gener us eu
assum whoever drug time go gener stay gener
howev boost integras inhibitor regimen mean drug-drug
think mani patient switch biktarvi given popul age
averag age like drug-drug interact like issu
therefor think forc switch biktarvi patient ahead cliff unlik
doc check note genvoya use frequent drug-drug
interfact covocistat boost drug like genvoya fraught resist
boost drug fallen favor
page
model gilead creat long-act therapi timelin
plan convert patient long-act oral drug inject product help off-set
patent cliff lce plan recent collabor
provid guidelin around la oral develop plan allow market
entri descovi complera odefsey go patent
phase
pdufa
stribild
atripla
complera
page
date announcedcollabor descriptiontherapeut areasd termsjuli durect commercialization dealcommerci deal l/a inject hiv hbv productsupfront payment durect potenti add development/regulatori mileston add sale base mileston tier royaltiesjuli partner lyndra therapeuticsdevelop/commerci ultra long-act oral hiv therapi exclus right platform ultra l/a formul relat hiv strh research compani report factset gilead scienc inc
hiv sensitivi convers biktari fv could go
page
switch app market sharepeak market share share ususex-usatripla dcf valu switch new total gilead total hiv revenu truvada hiv truvada prep descovi hiv descovi prep oral potenti launch str truvada/taf sale inc
page
accord cdc peopl us could benefit prep assum gild peak
penetr market
peopl truvada prep sinc
truvada report us sale truvada sale prep
octob descovi prep approv gild strategi convert truvada
prep onto descovi patent expir truvada
month convert mani truvada descovi prep
assum individu start truvada prep stay truvada go onto truvada
gener teva expect enter market sept
believ prep market remain truvada truvada gx
prep go descovi
believ truvada prep achiev peak sale descovi prep reach
peak sale patent expir
model also assum complianc prep hiv similar around
page
accord patient prep year season high-risk activ
phase discov studi evalu descovi prep vs truvada hiv prevent
transgend women show descovi met non-inferior criteria demonstr
favor bone renal safeti profil
truvada warn bone loss women osteoporosi may good
candid truvada howev descovi indic prep cisgend women
doc check note patient prep high-risk period short-term
exposur truvada would pose long-term safeti risk
prep discuss guidelin advis use truvada
page
pictur gilead give free drug prep- gilead view market
effect tailwind donat bottl uninsur ppl want prevent
bottl enough servic ppl per year eventu get job use insur
descovi prep
doc like safety/superior taf truvada descovi
instal base switch go taf-bas regimen
import analog chronic set safety/superior taf base
convert
market still under-penetrated penetr today
merck viiv also prep program
page
takeaway doc check treat prep patient
truvada gener big deal prep
descovi anoth option prep approv transgend women us
hiv infect person cisgend women
women osteoporosi may good candid truvada take descovi
prep indic current label men decreas kidney function bone densiti
concern could opt descovi prep
advantag descovi truvada hiv treatment clear descovi earli sign
benefit fewer impact kidney less bone loss continu treatment
prep treatment shorter-term year time season high-risk sexual behavior
patient go prep
problem prep access commerci insur typic pay prep medicaid
trump administr goal end hiv/aid epidem would like pick gener truvada first
brand truvada prep
commerci payer could look cost differ clinic data consid prep regimen
page
descovi prep contribut believ prep go truvada gener
biktarvi expir late share
also give credit long-act pipelin one potenti launch
model assum prep patient truvada like stay gener truvada instead
switch descovi prep
doc check suggest truvada gener prep market could maintain share descovi prep base
price
doc believ prep patient could go onto teva truvada gener payer may
inclin prefer gener truvada descovi prep base price
model prep split truvada gx descovi descovi patent
expir give share market truvada gx given preferenti price
note descovi prep studi cisgend women make
physician hiv infect patient popul plan start studi women
descovi prep conserv give contribut model
advantag descovi truvada treatment clear earli sign benefit
less kidney diseas less bone miner loss continu treatment prep on/off
drug lifelong high-risk life-styl patient kidney problems/decreas kidney function
may osteoporosi good candid truvada good candid
page
descovi prep contribut believ prep go truvada gener
descovi go take-over truvada prep clear given teva gener truvada
may import access low-incom patient current administr goal
toward end new infect
treatment vs prevent anoth consider prep patient prophylaxi take
short period live consid high-risk period ie high number sexual partner
high risk hiv acquisit patient monogam relationship patient may come
shorter durat prophylaxi doc check believ need avoid long-
term toxic necessari treatment hiv
page
believ truvada gx take major prep share despit descovi safeti benefit
conserv assum descovi prep reach peak penetr prep market
believ base doc check patient start truvada remain
truvada gener new patient start gener truvada
descovi prep contribut dcf addl penetr add
page
greater penetr descovi prep deliv double-digit upsid top bottom line
descovi prep penetr reach peak patent expir could see addit
growth top-line peak upsid bottom-lin
page
revenu sale revenu sale penetr descovi prep gilead scienc inc
convert gilead prep market descovi could add dcf
follow gener truvada launch assum share descovi prep add
addit dcf
recal descovi patent expir
page
page
pend label filgotinib commerci execut take time add dcf
highli competit inflamm market without manta data submit file
uncertain label statu black box warn concern sperm count
gild first foray inflamm market await commerci execut ra well
indic
abbv rinvoq price assum price filgotinib
peak sale peak penetr
assum lower price account commerci execut
page
sev ra patient us growth sev treat ra treatment patient treat treat market patient treat inc
filgotinib pipelin drug
glpg collabor allow addit data catalyst street give much
credit filgotinib pipelin
await data program commerci execut ra
page
accord glpg inflamm could market opportun
page
phase isabela ipf futil studi expect read
phase program isabela evalu ipf patient total
primari endpoint fvc declin week
posit data patient phase flora studi show fvc stabil period
function respiratori imag indic diseas stabil strong biomark reduct
page
includ model yet await commerci execut
autotaxin ipf progress lung fibrosi lead death
preval case us/eu
ipf high unmet need estim market
standard care drug pirfenidon nintedanib sale
autotaxin inhibitor reduc level autotaxin enzym import
gener signal molecul lypophosphatid acid lpa target autotaxin ipf
page
oa studi top-line data expect
develop osteoarthr potent select oral inhibitor admts-
key enzym degrad cartilag potenti disease-modifi agent
preval patient us/eu japan
disease-modifi treatment
potenti protect cartilag
phase studi oa patient show reduct arg well-toler
roccella phase studi knee oa fulli recruit readout
primari endpoint reduct cartilag loss week
secondari structur clinic paramet includ pain/funct safety/toler
page
advanc cell therapi program partnership manufactur invest
given current develop manufactur capabl wide establish
suppli limit continu make invest cell therapi infrastructur
april kite hold karnauska announc plan new state art facil
expand cell therapi product facil frederick counti md produc innov cell therapi
site expand kite abil manufactur varieti car-t therapi tcr cell
therapi ad ca netherland facil
juli kite announc plan new viral vector facil support development/
manufactur viral vector critic cell therapi new site build kite exist
invest help support grow cell therapi program
page
yescarta contribut dcf
driver growth
updat nccn guidelin real world data
better govern reimburs center smart get reimburs
on-going awar initi drive patient referr community-bas oncologist us
expand access patient across europ reimburs germani uk franc spain
new manufactur facil leas netherland support eu distribut expect fulli
oper current el segundo facil produc us eu
await dlbcl data clariti file yescarta expans dlbcl
page
pushback yescarta reimburs
increas medicar patient ultim goal get full
exampl octob establish inpati reimburs patient receiv
yescarta reimburs includ payment sever adjust drg new technolog add-on
payment yescarta cover one half cost yescarta may cover less
case outlier payment total payment may suffici
reimburs hospit yescarta payment methodolog like effect least
look final annual medicar ipp rule continu engag
improv car-t specif reimburs releas propos rule ipp contain
increas new technolog add-on payment us list price
current reimburs includ payment sever adjust diagnosi relat group drg
new technolog add-on payment cover half cost yescarta may cover
less total payment may suffici reimburs hospit cost care
patient receiv yescarta payment methodolog effect least sept
page
page
incom revenu hiv us us jak product revenu incom contract oper expens exclud itemsgain loss secur interest incom incom exc spec provis loss attribut non-controlling interest net ep ep chang non- option expens pre provis tax net ep ep share share gilead scienc inc
strh balanc sheet gilead
page
figur million except per share asset tax expens current current term market prepaid liabilitiesaccount rev/oth portion current lt liabil inc
page
figur million except per share flow oper net incom non-oper item depreci non- account current rev/oth chang flow invest capit market flow financingequ issuanc issuanc fx inc
model pt use dcf discount rate termin valu
appli higher discount rate instead account risk commerci
page
ebit base work present valu growth termin inc
risks/pushback thesi
pushback gilead new manag team may take time vision
implement ceo say expect evolut vs revolut one risk stock
doesnt move look like compani grow becom diversifi
rebutt gilead trade level impli zero credit prep beyond truvada capit alloc
includ pipelin think attract valu investor could see
enter name uncertain market also like manag vision
compani becom clearer year begin growth stock rather
pushback descovi take share truvada gener shortli
rebutt gilead expertis descovi show better safeti almost better efficaci trial
inject believ complianc deal prep popul health risk
believ past gilead switch patient got new patient onto better drug also
believ number
pushback gilead suffer lack catalyst
rebutt hard argu although data come jakafi jak new
indic manta studi evalu safeti believ investor confid jakafi take time
market crowd launch slow goe cellular therapi
page
inc biopharmaceut compani engag research develop
commerci medicin area unmet medic need primari area focu includ
oncolog inflamm respiratori diseas offer antivir product harvoni
vosevi brand compani found michael riordan june
headquart foster citi ca
gilead larg cap biotech compani construct entir new manag
team helm believ base hiv busi think offer stabl
revenu time think difficult see upsid name see
grow busi market oppi filgotinib larg expect jak uptak could
slow see show stori rate hold
valuat risk
pt deriv use probabl adjust dcf use discount rate appropri
larg cap stage biotech pipelin uncertainti assign share descovi prep
probabl peak sale filgotinib risk includ poorer biktarvi uptak price
 reimburs gener pipelin clinic trial risk failur alloc capit correctli analyst
elect benchmark perform rate stock subject report
compani mention note
robyn karnauska herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
